Signant Health recently initiated the #NoGoingBack movement, recognizing that COVID-19 forced the clinical research community to move trial conduct forward rapidly. This movement focuses on keeping in place the clinical research advancements gained during the COVID-19 pandemic and aggressively expanding thought leadership.
Visit the website to learn who is making a commitment to the progress made in drug development and trial conduct. This is an important movement that acknowledges the momentum gained this year for improving clinical research conduct globally.
Advarra salutes this recognition and hopes to see this sense of urgency live on for all forms of research, including oncology, rare disease, central nervous system, and many more important therapeutic areas. With mainstream attention focused on clinical trials, the future of implementing research innovations has arrived. And we can never go back!